Jennison Associates LLC Invests $46.89 Million in Humana Inc. (NYSE:HUM)

Jennison Associates LLC purchased a new stake in shares of Humana Inc. (NYSE:HUM) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 135,224 shares of the insurance provider’s stock, valued at approximately $46,885,000.

Several other large investors also recently bought and sold shares of HUM. Norges Bank bought a new stake in shares of Humana in the 4th quarter valued at about $676,800,000. Sanders Capital LLC purchased a new position in shares of Humana during the fourth quarter worth $489,300,000. Putnam Investments LLC grew its position in Humana by 550.3% during the fourth quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock valued at $400,808,000 after buying an additional 740,858 shares during the period. Allspring Global Investments Holdings LLC grew its position in Humana by 255.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 620,793 shares of the insurance provider’s stock valued at $215,241,000 after buying an additional 446,124 shares during the period. Finally, 1832 Asset Management L.P. grew its position in shares of Humana by 154.3% in the fourth quarter. 1832 Asset Management L.P. now owns 270,900 shares of the insurance provider’s stock valued at $124,021,000 after purchasing an additional 164,392 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

HUM stock traded up $1.61 during midday trading on Monday, hitting $370.43. 764,763 shares of the company traded hands, compared to its average volume of 1,792,530. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $530.54. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The business has a 50 day simple moving average of $350.26 and a 200-day simple moving average of $348.38. The stock has a market capitalization of $44.64 billion, a price-to-earnings ratio of 23.07, a price-to-earnings-growth ratio of 2.13 and a beta of 0.51.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. Humana’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the prior year, the business earned $9.38 earnings per share. As a group, equities research analysts predict that Humana Inc. will post 16.27 earnings per share for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 0.96%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on HUM shares. Wells Fargo & Company lowered their price target on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research report on Monday, April 8th. Baird R W raised shares of Humana to a “hold” rating in a research note on Thursday, May 30th. Piper Sandler started coverage on shares of Humana in a research note on Wednesday, June 26th. They set an “overweight” rating and a $392.00 target price on the stock. Jefferies Financial Group lowered their price target on shares of Humana from $411.00 to $381.00 and set a “buy” rating for the company in a report on Monday, April 22nd. Finally, TD Cowen lowered their price target on shares of Humana from $427.00 to $396.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Fourteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Humana has a consensus rating of “Hold” and an average target price of $409.55.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.